C4 Therapeutics Inc. (CCCC): Price and Financial Metrics


C4 Therapeutics Inc. (CCCC): $6.36

-0.51 (-7.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCCC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CCCC POWR Grades


  • Growth is the dimension where CCCC ranks best; there it ranks ahead of 64.02% of US stocks.
  • CCCC's strongest trending metric is Value; it's been moving down over the last 179 days.
  • CCCC's current lowest rank is in the Momentum metric (where it is better than 14.48% of US stocks).

CCCC Stock Summary

  • CCCC's went public 1.49 years ago, making it older than merely 2.58% of listed US stocks we're tracking.
  • Of note is the ratio of C4 Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.39% of US stocks have a lower such ratio.
  • With a price/sales ratio of 26.61, C4 Therapeutics Inc has a higher such ratio than 94.15% of stocks in our set.
  • Stocks that are quantitatively similar to CCCC, based on their financial statements, market capitalization, and price volatility, are SRRK, NTLA, MORF, NKTR, and CARA.
  • To dig deeper into the stock's financial statements, go to CCCC's page on browse-edgar?action=getcompany&CIK=0001662579.

CCCC Valuation Summary

  • CCCC's price/sales ratio is 57.3; this is 1407.89% higher than that of the median Healthcare stock.
  • CCCC's EV/EBIT ratio has moved up 8.8 over the prior 48 weeks.
  • CCCC's price/earnings ratio has moved up 8.2 over the prior 48 weeks.

Below are key valuation metrics over time for CCCC.

Stock Date P/S P/B P/E EV/EBIT
CCCC 2021-08-31 57.3 4.7 -22.3 -19.8
CCCC 2021-08-30 59.4 4.8 -23.1 -20.6
CCCC 2021-08-27 59.3 4.8 -23.1 -20.6
CCCC 2021-08-26 58.7 4.8 -22.8 -20.4
CCCC 2021-08-25 59.1 4.8 -23.0 -20.5
CCCC 2021-08-24 58.0 4.7 -22.6 -20.1

CCCC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CCCC has a Quality Grade of C, ranking ahead of 44.43% of graded US stocks.
  • CCCC's asset turnover comes in at 0.089 -- ranking 273rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CCCC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.089 1 -0.411
2020-12-31 0.128 1 -0.657

CCCC Price Target

For more insight on analysts targets of CCCC, see our CCCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.33 Average Broker Recommendation 1.44 (Moderate Buy)

CCCC Stock Price Chart Interactive Chart >

Price chart for CCCC

CCCC Price/Volume Stats

Current price $6.36 52-week high $51.21
Prev. close $6.87 52-week low $6.20
Day low $6.20 Volume 602,400
Day high $6.90 Avg. volume 827,919
50-day MA $15.21 Dividend yield N/A
200-day MA $31.00 Market Cap 310.35M

C4 Therapeutics Inc. (CCCC) Company Bio


C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.


CCCC Latest News Stream


Event/Time News Detail
Loading, please wait...

CCCC Latest Social Stream


Loading social stream, please wait...

View Full CCCC Social Stream

Latest CCCC News From Around the Web

Below are the latest news stories about C4 Therapeutics Inc that investors may wish to consider to help them evaluate CCCC as an investment opportunity.

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting – – Pre-clinical Data on CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted for Presentation at the AACR Annual Meeting – – CFT8634 Phase 1/2 Clinical Trial in Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors Expected to Initiate in 1H 2022; CFT1946 IND Application Submiss

Yahoo | February 24, 2022

What Is The Ownership Structure Like For C4 Therapeutics, Inc. (NASDAQ:CCCC)?

The big shareholder groups in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) have power over the company. Institutions will...

Yahoo | February 7, 2022

C4 Therapeutics (CCCC) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 12, 2022

Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy?

In this article we will analyze whether C4 Therapeutics, Inc. (NASDAQ:CCCC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Yahoo | January 12, 2022

C4 Therapeutics announces key 2022 milestones and priorities

C4 Therapeutics <> announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio.The initial Phase 1 data for CFT7455, a Novel

Seeking Alpha | January 10, 2022

Read More 'CCCC' Stories Here

CCCC Price Returns

1-mo -30.19%
3-mo -71.39%
6-mo -83.46%
1-year -83.10%
3-year N/A
5-year N/A
YTD -80.25%
2021 -2.81%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7141 seconds.